vs
CorMedix Inc.（CRMD）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
BRC Group Holdings, Inc.的季度营收约是CorMedix Inc.的1.5倍（$188.3M vs $128.6M）
CorMedix Inc.是一家处于商业阶段的生物制药企业，专注于开发及商业化用于预防和治疗感染性、炎症性及心肾疾病的创新治疗产品，核心管线针对导管相关血流感染，主要服务北美、欧洲的重症监护及长期透析患者群体。
CRMD vs RILY — 直观对比
营收规模更大
RILY
是对方的1.5倍
$128.6M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $128.6M | $188.3M |
| 净利润 | — | $90.3M |
| 毛利率 | 83.4% | 79.5% |
| 营业利润率 | 46.0% | 32.3% |
| 净利率 | — | 47.9% |
| 营收同比 | — | -21.9% |
| 净利润同比 | — | 1710.8% |
| 每股收益（稀释后） | $0.20 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRMDRILY
| Q4 25 | $128.6M | $188.3M | ||
| Q3 25 | $104.3M | $215.3M | ||
| Q2 25 | $39.7M | $188.2M | ||
| Q1 25 | $39.1M | $197.2M | ||
| Q4 24 | — | $241.0M | ||
| Q3 24 | — | $225.5M | ||
| Q2 24 | — | $256.0M | ||
| Q1 24 | — | $263.4M |
净利润CRMDRILY
| Q4 25 | — | $90.3M | ||
| Q3 25 | $108.6M | $91.1M | ||
| Q2 25 | $19.8M | $139.5M | ||
| Q1 25 | $20.6M | $-10.0M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | — | $-284.4M | ||
| Q2 24 | — | $-433.6M | ||
| Q1 24 | — | $-49.2M |
毛利率CRMDRILY
| Q4 25 | 83.4% | 79.5% | ||
| Q3 25 | 89.3% | 83.7% | ||
| Q2 25 | 95.3% | 81.3% | ||
| Q1 25 | 95.9% | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | — | 85.3% |
营业利润率CRMDRILY
| Q4 25 | 46.0% | 32.3% | ||
| Q3 25 | 49.2% | 30.4% | ||
| Q2 25 | 49.2% | 5.7% | ||
| Q1 25 | 51.5% | -31.2% | ||
| Q4 24 | — | -69.2% | ||
| Q3 24 | — | -36.4% | ||
| Q2 24 | — | -90.8% | ||
| Q1 24 | — | -6.1% |
净利率CRMDRILY
| Q4 25 | — | 47.9% | ||
| Q3 25 | 104.1% | 42.3% | ||
| Q2 25 | 49.9% | 74.1% | ||
| Q1 25 | 52.8% | -5.1% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | — | -126.1% | ||
| Q2 24 | — | -169.4% | ||
| Q1 24 | — | -18.7% |
每股收益（稀释后）CRMDRILY
| Q4 25 | $0.20 | $2.78 | ||
| Q3 25 | $1.26 | $2.91 | ||
| Q2 25 | $0.28 | $4.50 | ||
| Q1 25 | $0.30 | $-0.39 | ||
| Q4 24 | — | $-0.01 | ||
| Q3 24 | — | $-9.39 | ||
| Q2 24 | — | $-14.35 | ||
| Q1 24 | — | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $148.5M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $405.3M | $-171.5M |
| 总资产 | $826.1M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CRMDRILY
| Q4 25 | $148.5M | $226.6M | ||
| Q3 25 | $55.7M | $184.2M | ||
| Q2 25 | $190.7M | $267.4M | ||
| Q1 25 | $77.5M | $138.3M | ||
| Q4 24 | — | $146.9M | ||
| Q3 24 | — | $159.2M | ||
| Q2 24 | — | $236.9M | ||
| Q1 24 | — | $190.7M |
总债务CRMDRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CRMDRILY
| Q4 25 | $405.3M | $-171.5M | ||
| Q3 25 | $374.1M | $-260.5M | ||
| Q2 25 | $220.6M | $-351.7M | ||
| Q1 25 | $114.9M | $-496.8M | ||
| Q4 24 | — | $-488.2M | ||
| Q3 24 | — | $-497.6M | ||
| Q2 24 | — | $-218.3M | ||
| Q1 24 | — | $228.4M |
总资产CRMDRILY
| Q4 25 | $826.1M | $1.7B | ||
| Q3 25 | $750.9M | $1.7B | ||
| Q2 25 | $252.6M | $1.5B | ||
| Q1 25 | $149.6M | $1.5B | ||
| Q4 24 | — | $1.8B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $3.2B | ||
| Q1 24 | — | $5.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $94.5M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $92.7M | — |
| 自由现金流率自由现金流/营收 | 72.1% | — |
| 资本支出强度资本支出/营收 | 1.3% | — |
| 现金转化率经营现金流/净利润 | — | 0.29× |
| 过去12个月自由现金流最近4个季度 | $172.8M | — |
8季度趋势，按日历期对齐
经营现金流CRMDRILY
| Q4 25 | $94.5M | $26.2M | ||
| Q3 25 | $30.9M | $-60.6M | ||
| Q2 25 | $30.0M | $-25.6M | ||
| Q1 25 | $19.7M | $184.0K | ||
| Q4 24 | — | $-2.7M | ||
| Q3 24 | — | $19.5M | ||
| Q2 24 | — | $111.5M | ||
| Q1 24 | — | $135.4M |
自由现金流CRMDRILY
| Q4 25 | $92.7M | — | ||
| Q3 25 | $30.4M | — | ||
| Q2 25 | $30.0M | — | ||
| Q1 25 | $19.7M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率CRMDRILY
| Q4 25 | 72.1% | — | ||
| Q3 25 | 29.1% | — | ||
| Q2 25 | 75.4% | — | ||
| Q1 25 | 50.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度CRMDRILY
| Q4 25 | 1.3% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率CRMDRILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | 0.28× | -0.66× | ||
| Q2 25 | 1.51× | -0.18× | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRMD
| Acquisition Of Melinta | $52.9M | 41% |
| Melinta Portfolio | $45.5M | 35% |
| Other | $18.6M | 14% |
| Contract Revenue | $7.4M | 6% |
| BARDA Agreement | $4.2M | 3% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
